Age Related Macular Degeneration May be Prevented with Macugen

Age-related macular degeneration (AMD) is the leading cause of blindness in older patients in US and the developed world. Pegaptanib sodium (Macugen) is a new treatment for exudative AMD, and has been shown to stabilize vision in approximately 70 percent of cases.

The researchers found that at week 54, 76 percent of patients in group 1 receiving pegaptanib lost fewer than 15 letters or three lines of vision on the ETDRS eye chart, compared with 50 percent of patients undergoing usual care. A number of patients treated with pegaptanib even regained some sight.

The study found that early detection and treatment of age-related macular degeneration with pegaptanib sodium may enable AMD patients to maintain and, in some cases, regain vision.

As a result, the Jules Stein Eye Institute is launching a prospective, open-label, multi-center trial to evaluate the efficacy and safety of pegaptanib in 40 patients with early onset of AMD.

Link


Filed under Eye Treatment, Macular Degeneration

You may also like to read

No Responses to “Age Related Macular Degeneration May be Prevented with Macugen”

  1. Dee Martz Says:

    My father, who is 80 years old, has MD. We have sought every area of help available, and it simply is what it is. However, I wonder if you know of any support groups, groups to assist in finding activities or ways of attending activities without becoming frustrated and choosing to stay inside.

Leave a Reply



Please enter the code shown below ( to verify that you are human ) before you click Submit Comment.